Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer
- PMID: 23410972
- DOI: 10.1016/j.ccr.2013.01.002
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer
Abstract
Early-onset prostate cancer (EO-PCA) represents the earliest clinical manifestation of prostate cancer. To compare the genomic alteration landscapes of EO-PCA with "classical" (elderly-onset) PCA, we performed deep sequencing-based genomics analyses in 11 tumors diagnosed at young age, and pursued comparative assessments with seven elderly-onset PCA genomes. Remarkable age-related differences in structural rearrangement (SR) formation became evident, suggesting distinct disease pathomechanisms. Whereas EO-PCAs harbored a prevalence of balanced SRs, with a specific abundance of androgen-regulated ETS gene fusions including TMPRSS2:ERG, elderly-onset PCAs displayed primarily non-androgen-associated SRs. Data from a validation cohort of > 10,000 patients showed age-dependent androgen receptor levels and a prevalence of SRs affecting androgen-regulated genes, further substantiating the activity of a characteristic "androgen-type" pathomechanism in EO-PCA.
Copyright © 2013 Elsevier Inc. All rights reserved.
Comment in
-
Molecular archeology: unearthing androgen-induced structural rearrangements in prostate cancer genomes.Cancer Cell. 2013 Feb 11;23(2):133-5. doi: 10.1016/j.ccr.2013.01.019. Cancer Cell. 2013. PMID: 23410968 Free PMC article.
-
[Brief communication - cause of prostate cancer in younger men identified ].Aktuelle Urol. 2013 Mar;44(2):99-100. doi: 10.1055/s-0033-1343919. Epub 2013 Apr 16. Aktuelle Urol. 2013. PMID: 23592286 German. No abstract available.
-
Commentary on "integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer." Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, Jäger N, Gu L, Bogatyrova O, Stütz AM, Claus R, Eils J, Eils R, Gerhäuser C, Huang PH, Hutter B, Kabbe R, Lawerenz C, Radomski S, Bartholomae CC, Fälth M, Gade S, Schmidt M, Amschler N, Haß T, Galal R, Gjoni J, Kuner R, Baer C, Masser S, von Kalle C, Zichner T, Benes V, Raeder B, Mader M, Amstislavskiy V, Avci M, Lehrach H, Parkhomchuk D, Sultan M, Burkhardt L, Graefen M, Huland H, Kluth M, Krohn A, Sirma H, Stumm L, Steurer S, Grupp K, Sültmann H, Sauter G, Plass C, Brors B, Yaspo ML, Korbel JO, Schlomm T, Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.: Cancer Cell 2013;23(2):159-70.Urol Oncol. 2014 Feb;32(2):212. doi: 10.1016/j.urolonc.2013.08.018. Urol Oncol. 2014. PMID: 24445294
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
